Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 47,425 shares of Aimmune Therapeutics stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the transaction, the insider now owns 34,300 shares of the company’s stock, valued at $1,181,292. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Aimmune Therapeutics, Inc. (AIMT) traded down 1.05% on Wednesday, reaching $31.24. 737,675 shares of the company traded hands. Aimmune Therapeutics, Inc. has a one year low of $14.87 and a one year high of $37.50. The stock’s 50 day moving average price is $25.22 and its 200 day moving average price is $25.22. The company’s market capitalization is $1.58 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts predict that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Aimmune Therapeutics, Inc. (AIMT) Insider Sells $1,633,317.00 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/aimmune-therapeutics-inc-aimt-insider-sells-1633317-00-in-stock.html.

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC grew its position in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares during the last quarter. Legal & General Group Plc grew its position in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares during the last quarter. Voya Investment Management LLC grew its position in Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Aimmune Therapeutics during the 2nd quarter valued at about $333,000. Finally, American International Group Inc. grew its position in Aimmune Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 1,070 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

A number of brokerages have recently issued reports on AIMT. Credit Suisse Group lifted their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday. Wedbush reiterated an “outperform” rating and set a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a report on Monday. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Saturday. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of “Hold” and a consensus target price of $51.00.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.